NEW YORK (TheStreet) -- Radius Health (RDUS - Get Report) stock soared by 25.44% to $33.87 on heavy trading volume on Monday, after biotechnology company Amgen (AMGN) released data from a late-stage clinical trial.
The data indicated that women who used Amgen's osteoporosis drug romosozumab experienced a 73% decline in their risk of developing a spine fracture compared to a control group.
The report boosted shares of Radius Health, as the company's own experimental osteoporosis drug abaloparatide caused an 86% decline in the risk of developing a spine fracture compared to a control group.
Based in Waltham, MA, Radius Health is a biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases.
About 5.96 million shares of Radius Health were traded today, well above the company's average trading volume of roughly 1.14 million shares per day.RDUS data by YCharts